January 5, 2017
Via EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Mail Stop 4546
Washington, D.C. 20549
Attn: Jim B. Rosenberg, Senior Assistant Chief Accountant
Re: |
AMAG Pharmaceuticals, Inc. |
|
|
Form 10-K for the Fiscal Year Ended December 31, 2015 |
|
|
Filed February 24, 2016 |
|
|
Form 8-K |
|
|
Furnished November 3, 2016 |
|
|
File No. 1-10865 |
|
Dear Mr. Rosenberg:
On behalf of AMAG Pharmaceuticals, Inc. (the Company), the Company hereby advises the staff (the Staff) of the Securities and Exchange Commission (the Commission) that the Company has received the Staffs letter dated December 23, 2016 (the Comment Letter), regarding the Commissions review of the Companys Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and the Companys Current Report on Form 8-K furnished November 3, 2016. The Company respectfully requests an extension until January 25, 2017 to respond to the Comment Letter in order to provide sufficient time for the Company to prepare the response. The Company is committed to responding to the Comment Letter promptly and intends to provide a response to the Staff no later than January 25, 2017. Should you have any questions regarding the request made herein, please do not hesitate to contact me at (617) 570-1762. Thank you very much for your courtesy and cooperation in this matter.
|
Sincerely, |
|
|
|
/s/ Jacqueline Mercier |
|
Jacqueline Mercier, Esq. |
|
Goodwin Procter LLP |
cc: |
Frank E. Thomas, AMAG Pharmaceuticals, Inc. |
|
Joseph D. Vittiglio, AMAG Pharmaceuticals, Inc. |
|
Edward Myles, AMAG Pharmaceuticals, Inc. |
|
Ettore A. Santucci, Goodwin Procter LLP |